The International Aortic Summit, co-founded by Joseph V. Lombardi MD, will hold its second annual meeting in Venice from June 21st – 23rd, 2012. The world leaders in aortic surgery will give presentations on their research and new technology applications to aortic disease.

“We are fortunate to involve so many fantastic aortic surgeons this year,” reports, Dr. Lombardi , meeting Co-Chairman. The meeting this year will be focused on new technology and techniques. “This summit will prove to be a tremendous opportunity to share ideas on aortic disease and education, ” says Dr Lombardi, Chief of Vascular and Endovascular Surgery at Cooper University Hospital.

Learn more about the 2012 International Aortic Summit, including a full list of faculty members, topics and online registration information, by visiting ias2012venice.com.

Journal of Vascular Society
January 2012

Cooper Vascular Surgeons discuss the benefits of a thriving Vascular Surgery program to a health system in this article in the Journal of Vascular Surgery.  Drs. Joseph Lombardi and Nyali Taylor demonstrate how the coordinated relationship between vascular surgeons and hospitals results in a thriving vascular program and a healthy hospital margin.

To read the full article click HERE.

Dr. Joseph Lombardi

Study investigators reported positive steps in Cook Medical’s efforts to gain FDA approval of the treatment assessed in the STABLE clinical trial, designed to evaluate the safety and efficacy of a proximal endograft and a distal uncovered stent for the endovascular treatment of Type B aortic dissection for purposes of seeking FDA approval. The findings were presented by Dr. Joseph Lombardi at the 37th annual VEITHsymposium. The trial is the first and only one of its kind to focus on a device uniquely designed for the endovascular treatment of Type B aortic dissection. The system as a whole is an investigational device not available in the United States.

“Open surgery to repair dissection can take a devastating toll on a patient, and we hope the STABLE trial final results support an endovascular solution.”

“The initial data for the STABLE clinical trial show promise,” said Joseph Lombardi, M.D., the study’s principal investigator and chief of vascular and endovascular surgery at Cooper University Hospital and associate professor of surgery at the Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey. “Aortic dissection can be a life-threatening condition, and surgical intervention is a highly invasive procedure. If confirmed, these initial results are a positive step toward proving the safety and efficacy of a minimally invasive treatment for aortic dissection.”

Read the full story

We celebrated the opening of our new multi-specialty facility in Willingboro (651 John F. Kennedy Way) with a ribbon-cutting ceremony and tour on Monday night.

The 11,000 square feet of practice space is in the heart of Burlington County and will offer patients an array of services, including: Podiatry, Vascular Surgery, Urology, Dermatology, Nephrology, Rheumatology as well as Primary Care.

Facility Features:

• 26 exam rooms
• 3 procedure rooms
• Convenient parking

(Camden, New Jersey) Joseph V. Lombardi, M.D., joins the Department of Surgery at Cooper as the new Head of Vascular Surgery. He is a prominent vascular surgeon with expertise in minimally invasive endovascular therapy. Dr. Lombardi, is pioneering the treatment of thoracic aortic dissection with endovascular grafts and stents. He serves as Global Principal Investigator for the STABLE trial, investigating the use of endovascular therapy to treat complicated Type B Thoracic Aortic Dissection.

“We are developing a masterful team of experts in surgery and Dr. Lombardi brings a talent unseen in our region,” said Jeffrey Carpenter, M.D., Chief of the Department of Surgery at Cooper.

Read the full story